We are an oncology company focused on the clinical development of novel therapies for cancer. Our lead programs include a potential best-in-class HDAC inhibitor, Pracinostat, a novel mitochondrial inhibitor, ME-344, and a PI3-kinase delta inhibitor, PWT143.
[ Read more ]
MEI Pharma Reports High Response Rates in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia
[ June 10, 2014 ]
MEI Pharma Initiates Clinical Study of Mitochondrial Inhibitor ME-344 in Small Cell Lung and Ovarian Cancers
[ May 5, 2014 ]
Click here for our 2013 Annual Review